WuXi Biologics (Cayman) EBIT

WuXi Biologics (Cayman) (WXIBF) currently reports a EBIT of $13B as of June 2026. That compares with $7.6B in the prior-year period — up 76.3% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore WuXi Biologics (Cayman)'s EBIT history and peer comparisons.

WuXi Biologics (Cayman)'s EBIT increased from $7.6B to $13B — a 76.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

WuXi Biologics (Cayman)'s EBIT of $13B is lower than the Healthcare sector average of $99B. That is roughly 86.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

WuXi Biologics (Cayman) reported $13B in EBIT as of June 2026. That compares with $7.6B in the prior-year period — up 76.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $13B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for WuXi Biologics (Cayman), and consider following WXIBF for alerts when major investors trade the stock.